Juno Therapeutics, Inc. - FORM S-1 - EX-10.12(B) - AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT - November 17, 2014

Attached files

file filename
S-1 - FORM S-1 - Juno Therapeutics, Inc.d772541ds1.htm
EX-10.12(A) - EXCLUSIVE LICENSE AGREEMENT, SEATTLE CHILDREN'S HOSPITAL - Juno Therapeutics, Inc.d772541dex1012a.htm
EX-10.1 - EXCLUSIVE LICENSE AGREEMENT - Juno Therapeutics, Inc.d772541dex101.htm
EX-10.20 - FORM OF RESTRICTED STOCK AGREEMENT UNDER THE 2013 EQUITY INCENTIVE PLAN - Juno Therapeutics, Inc.d772541dex1020.htm
EX-10.8 - MASTER SPONSORED RESEARCH AGREEMENT - Juno Therapeutics, Inc.d772541dex108.htm
EX-10.16 - OFFER LETTER AGREEMENT, MARK FROHLICH, M.D. - Juno Therapeutics, Inc.d772541dex1016.htm
EX-10.14 - OFFER LETTER AGREEMENT, HANS E. BISHOP - Juno Therapeutics, Inc.d772541dex1014.htm
EX-10.9 - MASTER CLINICAL STUDY AGREEMENT, MEMORIAL SLOAN-KETTERING CANCER CENTER - Juno Therapeutics, Inc.d772541dex109.htm
EX-10.21 - FORM OF STOCK OPTION GRANT NOTICE & OPTION AGREEMENT UNDER 2013 EQUITY INC PLAN - Juno Therapeutics, Inc.d772541dex1021.htm
EX-10.15 - OFFER LETTER AGREEMENT, BERNARD J. CASSIDY - Juno Therapeutics, Inc.d772541dex1015.htm
EX-10.10 - LETTER AGREEMENT, MEMORIAL SLOAN KETTERING CANCER CENTER - Juno Therapeutics, Inc.d772541dex1010.htm
EX-4.1 - AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT - Juno Therapeutics, Inc.d772541dex41.htm
EX-10.26 - SUBLEASE AGREEMENT, SEATTLE BIOMEDICAL RESEARCH INSTITUTE - Juno Therapeutics, Inc.d772541dex1026.htm
EX-10.7(A) - EXCLUSIVE LICENSE AGREEMENT, MEMORIAL SLOAN-KETTERING CANCER CENTER - Juno Therapeutics, Inc.d772541dex107a.htm
EX-10.18 - FORM OF DIRECTOR AND EXECUTIVE OFFICER INDEMNIFICATION AGREEMENT - Juno Therapeutics, Inc.d772541dex1018.htm
EX-10.7(B) - AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT, MEMORIAL SLOAN KETTERING CANCER - Juno Therapeutics, Inc.d772541dex107b.htm
EX-10.17 - OFFER LETTER AGREEMENT, STEVEN D. HARR, M.D. - Juno Therapeutics, Inc.d772541dex1017.htm
EX-10.11 - EXCLUSIVE LICENSE AGREEMENT, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. - Juno Therapeutics, Inc.d772541dex1011.htm
EX-23.1 - CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Juno Therapeutics, Inc.d772541dex231.htm
EX-10.5 - LETTER AGREEMENT, FRED HUTCHINSON CANCER RESEARCH CENTER - Juno Therapeutics, Inc.d772541dex105.htm
EX-10.19 - 2013 EQUITY INCENTIVE PLAN, AS AMENDED - Juno Therapeutics, Inc.d772541dex1019.htm
EX-10.13 - SPONSORED RESEARCH AGREEMENT, SEATTLE CHILDREN'S HOSPITAL - Juno Therapeutics, Inc.d772541dex1013.htm

Exhibit 10.12B

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Amendment No. 1

to the

Exclusive License Agreement

This Amendment No. 1, dated as of August 4, 2014, is entered into between Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, a Washington non-profit corporation (“Licensor”) and Juno Therapeutics, Inc., a Delaware corporation (“Licensee”)

 

  •   Licensor and Licensee previously entered into an Exclusive License Agreement, dated as of February 13, 2014 (“Original Agreement”).

 

  •   Licensor and Licensee want to amend the Original Agreement to add patent application(s) to the Licensed Patents, all as set forth below.

Accordingly, the parties agree as follows:

1. Exhibit A. Exhibit A is hereby amended to add the following patent application(s):

 

[***]    [***]    [***]
[***]    [***]    [***]
[***]    [***]    [***]

2. Exhibit A Restated. Exhibit A, in full, now reads as follows:

 

[***]    [***]    [***]
[***]    [***]    [***]
[***]    [***]    [***]
[***]    [***]    [***]
[***]    [***]    [***]
[***]    [***]    [***]

3. Full Force and Effect. Except as modified by this Amendment No. 1, all other terms of the Original Agreement will remain in full force and effect.

Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute and Juno Therapeutics, Inc., Exclusive License Agreement, Amendment 1, Page 2 of 2

 

 

 

 

JUNO THERAPEUTICS, INC.    

SEATTLE CHILDREN’S HOSPITAL

D/B/A SEATTLE CHILDREN’S

RESEARCH INSTITUTE

By:  

/s/ H. Bishop

     By:  

/s/ James B. Hendricks, PhD

Name:  

H. Bishop

     Name:  

James B. Hendricks, PhD

Title:  

C.E.O.

     Title:  

President, Seattle Children’s Research Institute

 

2

Juno Therapeutics, Inc. Reports